First Generic Pimobendan Breaks Vetmedin's 19-Year Monopoly

For nearly two decades, a dog in congestive heart failure that needed pimobendan in an FDA-approved tablet had one option, and the company that made it set the price. That ended this week.

Cronus Pharma began selling the first FDA-approved generic of Vetmedin on June 9, opening price competition in one of the highest-volume drug categories in companion-animal medicine. For clinic owners, distributors, and anyone modeling the economics of a veterinary practice, a single-source cardiac staple just became a two-source one.

Cronus Pharma launches the first FDA-approved generic pimobendan

The product is a chewable pimobendan tablet that the FDA approved in 2024 under ANADA #200-728 as a bioequivalent of Boehringer Ingelheim's Vetmedin, now reaching the US market. It carries the same core indication as the brand: management of mild, moderate, or severe congestive heart failure in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM).

Cronus is shipping four strengths, 1.25 mg, 2.5 mg, 5 mg, and 10 mg, in half-scored tablets at 50 per bottle, through national and regional distributors. That distribution footprint matters more than the dosing detail. It means the generic reaches clinic shelves through the same wholesalers vets already buy from, rather than requiring a new ordering relationship.

Until now, the only alternative to branded Vetmedin was compounded pimobendan, which the FDA does not approve and which carries no bioequivalence guarantee. Cronus is positioning its tablet squarely against that gap: an approved, consistently manufactured option at a generic price point.

The company is not a new entrant. East Brunswick-based Cronus runs its own research, manufacturing, and sales, and lists 76 approved products with 26 on the market. It built the same playbook in livestock with Doraject, the first generic equivalent to Dectomax. Pimobendan is the same move aimed at companion animals.

Generic competition resets the math on a cardiac staple

Heart disease reaches roughly one in ten dogs over a lifetime, per Boehringer Ingelheim, and pimobendan has been the standard of care for the failing canine heart for a generation. Vetmedin has carried that demand alone since 2007. A drug that sells in that volume, with daily lifelong dosing per patient, is exactly the kind of franchise a generic is built to erode.

The first effect operators will feel is price. Branded pimobendan has had no approved competitor setting a floor, which gave Boehringer pricing latitude. An approved generic changes the negotiation. Distributors gain a second SKU to position, clinics gain a cheaper line item on a high-frequency prescription, and pet owners on fixed cardiac-care budgets gain a lower-cost refill. None of that requires a clinical argument. Bioequivalence is the argument.

The second effect is on compounding. A meaningful share of price-sensitive pimobendan demand had drifted to compounded versions that live in a regulatory gray zone. An FDA-approved generic at a competitive price pulls that demand back toward approved product. That is a quieter story than the brand-versus-generic headline, but for a vet weighing liability and consistency against cost, it removes the reason to compound.

The timing is the part worth sitting with. Boehringer spent the last 18 months moving Vetmedin upmarket, not defending the treatment segment. It launched Vetmedin Solution, an oral liquid, in late 2024, and in January 2026 won an expanded label to delay heart-failure onset in dogs with preclinical Stage B2 MMVD, a far larger pool of patients than those already in failure.

Read together, the two moves describe a strategy. The generic takes the mature treatment segment on price. The brand retreats to newer formulations and a prevention indication where it still owns the label and the data. It is the standard pharma response to a patent cliff, now playing out in animal health, where it is still rare enough to be instructive.

What the next generic battle in animal health signals

The near-term question is how Boehringer defends. It can fight the generic on price in the treatment segment, or it can cede share there and push veterinarians toward the Stage B2 prevention label and the oral solution, where it has no generic competition yet. The second path is more likely and more telling, because it is the one that protects margin.

Watch distributor behavior next. Whether the big national wholesalers actively position the Cronus tablet, or simply stock it, will determine how fast the price effect reaches clinics.

Watch Cronus's pipeline too. With 76 approved products and several more awaiting FDA clearance, the company has signaled it intends to do to other branded companion-animal staples what it just did to Vetmedin. The pimobendan launch is less a single event than a template.

Source: Cronus Pharma Introduces Pimobendan Chewable Tablets via Business Wire